MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Wall Street Was Wrong About Boston Scientific

Wall Street analysts cheered Boston Scientific when it acquired Guidant in the largest deal in medical device industry history. But the firm's share price and bond ratings have taken a beating since then, making those analysts look bad, reports the New York Times. Its stock has dipped below even what the most bearish analysts expected, and its bond ratings are now at junk level.

And things could get even worse, as Wall Street did not like the firm's decision to not sell off a stake in its endosurgery unit. The debt load and legal liabilities from the Guidant deal were expected, though perhaps not to this extent. What was not expected was that sales of ICDs and, especially, drug-eluting stents would fall off -- the latter in response to concerns about clotting unknown at the time of the deal. The endosurgery business has no such problems, which is why Boston Scientific wants to hold onto it for now. Wall Street analysts would prefer the firm sell a stake in it to raise money to pay down debt, but their track record on what's best for the company hasn't been very good recently, now, has it?

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish